SCHEDULE: Voss Capital Discloses 5.3% Stake in Actuate Therapeutics

Voss Capital, LP and affiliated entities have reported a 5.3% beneficial ownership stake in Actuate Therapeutics, Inc. common stock.

Summary

• Voss Capital, LP, Travis W. Cocke, Voss Advisors GP, LLC, Voss Value Master Fund, L.P., and Voss Value-Oriented Special Situations Fund, L.P. collectively reported beneficial ownership of 1,227,756 shares of Actuate Therapeutics, Inc. common stock.
• This aggregate ownership represents 5.3% of the outstanding common stock of Actuate Therapeutics, Inc.
• The percentage is based on 23,243,328 shares outstanding as of September 30, 2025, as disclosed in the Issuer's Form 10-Q filed on November 13, 2025.
• The event requiring this filing occurred on December 15, 2025.
• The filing states that the securities were not acquired for the purpose of changing or influencing control of the issuer, other than activities solely in connection with a nomination under Rule 240.14a-11.

Sentiment

Score: 6

Explanation: The disclosure of a significant 5.3% stake by an investment firm like Voss Capital is generally viewed as a positive signal of investor confidence, although the filing itself is a routine regulatory requirement and does not contain operational or financial news.

Positives

• A significant stake by an investment firm like Voss Capital could signal confidence in Actuate Therapeutics' future prospects.
• The disclosure of a 5.3% stake indicates a notable institutional investor interest in the company.

Future Outlook

NA

Industry Context

This Schedule 13G filing indicates that Voss Capital, an investment firm, has taken a significant passive stake in Actuate Therapeutics. Such disclosures are common for institutional investors crossing the 5% ownership threshold, signaling their investment position without necessarily implying an intent to control the company. It provides transparency regarding major shareholders.

Stakeholder Impact

• Shareholders: Existing shareholders may view the entry of a significant institutional investor as a positive sign, potentially increasing confidence and liquidity.
• Management: Management gains a new significant shareholder whose interests may align with long-term value creation, though the filing explicitly states no intent to influence control beyond potential nominations.

Key Dates

Recommendation

While the entry of a new significant institutional investor like Voss Capital is generally a positive indicator of confidence, a Schedule 13G filing primarily reports ownership and does not provide new operational or financial data to warrant a 'buy' or 'sell' recommendation. Investors should 'hold' and monitor future developments, including any further filings or company announcements, to assess the long-term implications of this stake.

Keywords

Actuate Therapeutics, Voss Capital, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Investor, Equity Stake, SEC Filing